Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels

Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels

Background: Two forms of PCSK9, an intact and a furin cleaved form, circulate in blood.

Bibliographic Details
Main Authors:	Lipari, Michael T., Li, Wei, Moran, Paul, Kong-Beltran, Monica, Sai, Tao, Lai, Joyce, Lin, S. Jack, Kolumam, Ganesh, Zavala-Solorio, Jose, Izrael-Tomasevic, Anita, Arnott, David, Wang, Jianyong, Peterson, Andrew S., Kirchhofer, Daniel
Format:	Online
Language:	English
Published:	American Society for Biochemistry and Molecular Biology 2012
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527935/

Similar Items

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gene Is a Risk Factor of Large-Vessel Atherosclerosis Stroke
by: Abboud, Shérine, et al.
Published: (2007)

Common Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Epitopes Mediate Multiple Routes for Internalization and Function
by: DeVay, Rachel M., et al.
Published: (2015)

Molecular and cellular function of the proprotein convertase subtilisin/kexin type 9 (PCSK9)
by: Schulz, Rainer, et al.
Published: (2015)

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)
by: Canuel, Maryssa, et al.
Published: (2013)

Efficacy and safety of proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, a post-commercialization study
by: Joshua Choi, et al.
Published: (2017-07-01)

Correlation between serum levels of proprotein convertase subtilisin/kexin type 9 (PCSK9) and atherogenic lipoproteins in patients with coronary artery disease
by: Nozue, Tsuyoshi, et al.
Published: (2016)

Polydatin ameliorates lipid and glucose metabolism in type 2 diabetes mellitus by downregulating proprotein convertase subtilisin/kexin type 9 (PCSK9)
by: Wang, Yu, et al.
Published: (2016)

Low Density Lipoprotein Binds to Proprotein Convertase Subtilisin/Kexin Type-9 (PCSK9) in Human Plasma and Inhibits PCSK9-mediated Low Density Lipoprotein Receptor Degradation*
by: Kosenko, Tanja, et al.
Published: (2013)

HIV and Hepatitis C–Coinfected Patients Have Lower Low‐Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent “PCSK9–Lipid Paradox”
by: Kohli, Payal, et al.
Published: (2016)

Molecular characterization of proprotein convertase subtilisin/kexin type 9-mediated degradation of the LDLR
by: Wang, Yan, et al.
Published: (2012)

Proprotein Convertase Subtilisin/Kexin Type 9: From the Discovery to the Development of New Therapies for Cardiovascular Diseases
by: Ferri, Nicola
Published: (2012)

Current and emerging treatments for hypercholesterolemia: A focus on statins and proprotein convertase subtilisin/kexin Type 9 inhibitors for perioperative clinicians
by: Trentman, Terrence L., et al.
Published: (2016)

Development of proprotein convertase subtilisin/kexin type 9 inhibitors and the clinical potential of monoclonal antibodies in the management of lipid disorders
by: Gupta, Sanjiv
Published: (2016)

Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9
by: Gu, Hong-mei, et al.
Published: (2015)

Characterization of a quantitative method to measure free proprotein convertase subtilisin/kexin type 9 in human serum
by: Colbert, Alexander, et al.
Published: (2014)

Policosanol Attenuates Statin-Induced Increases in Serum Proprotein Convertase Subtilisin/Kexin Type 9 When Combined with Atorvastatin
by: Guo, Yuan-Lin, et al.
Published: (2014)

Proprotein convertase subtilisin/kexin type 9 expression is transiently up-regulated in the acute period of myocardial infarction in rat
by: Zhang, Yan, et al.
Published: (2014)

Characterization of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Trafficking Reveals a Novel Lysosomal Targeting Mechanism via Amyloid Precursor-like Protein 2 (APLP2)
by: DeVay, Rachel M., et al.
Published: (2013)

Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study
by: Kastelein, John J.P., et al.
Published: (2016)

Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture
by: Mbikay, Majambu, et al.
Published: (2014)

The proprotein convertase furin is required for trophoblast syncytialization
by: Zhou, Z, et al.
Published: (2013)

Proprotein Convertase Subtilisin/Kexin Type 3 Promotes Adipose Tissue-Driven Macrophage Chemotaxis and Is Increased in Obesity
by: Kappert, Kai, et al.
Published: (2013)

Proprotein Convertase Subtilisin/Kexin Type 9 Gene E670G Polymorphism Interacts with Alcohol Consumption to Modulate Serum Lipid Levels
by: Aung, Lynn Htet Htet, et al.
Published: (2012)

Proprotein Convertase Subtilisin/Kexin Type 9 Gene E670G Polymorphism Interacts with Alcohol Consumption to Modulate Serum Lipid Levels
by: Lynn Htet Htet Aung, Rui-Xing Yin, Dong-Feng Wu, Xiao-Li Cao, Xi-Jiang Hu, Lin Miao
Published: (2013-01-01)

Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells
Published: (2016)

Efficiency and Safety of Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody on Hypercholesterolemia: A Meta-Analysis of 20 Randomized Controlled Trials
by: Li, Chuanwei, et al.
Published: (2015)

Relationship Between Low‐Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid‐Lowering Strategies
by: Rey, Jacques, et al.
Published: (2016)

Plasma Levels of Proprotein Convertase Subtilisin/Kexin Type 9 Are Elevated in Patients With Peripheral Artery Disease and Associated With Metabolic Disorders and Dysfunction in Circulating Progenitor Cells
by: Chao, Ting‐Hsing, et al.
Published: (2016)

Proprotein Convertase Furin Regulates Apoptosis and Proliferation of Granulosa Cells in the Rat Ovary
by: Yang, Xiaokui, et al.
Published: (2013)

Furin Is the Major Proprotein Convertase Required for KISS1-to-Kisspeptin Processing
by: Harihar, Sitaram, et al.
Published: (2014)

The Proprotein Convertase Furin Contributes to Rhabdomyosarcoma Malignancy by Promoting Vascularization, Migration and Invasion
by: Jaaks, Patricia, et al.
Published: (2016)

Preferential apelin-13 production by the proprotein convertase PCSK3 is implicated in obesity☆
by: Shin, Kyungsoo, et al.
Published: (2013)

β‐Estradiol results in a proprotein convertase subtilisin/kexin type 9‐dependent increase in low‐density lipoprotein receptor levels in human hepatic HuH7 cells
by: Starr, Amanda E., et al.
Published: (2015)

The associations between proprotein convertase subtilisin/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis
by: Cai, Gaojun, et al.
Published: (2015)

Comparative analysis of expression of the proprotein convertases furin, PACE4, PC1 and PC2 in human lung tumours.
by: Mbikay, M., et al.
Published: (1997)

Liver-Specific Inactivation of the Proprotein Convertase FURIN Leads to Increased Hepatocellular Carcinoma Growth
by: Declercq, Jeroen, et al.
Published: (2015)

The Proprotein Convertase KPC-1/Furin Controls Branching and Self-avoidance of Sensory Dendrites in Caenorhabditis elegans
by: Salzberg, Yehuda, et al.
Published: (2014)

A Homolog of Subtilisin-Like Proprotein Convertase 7 Is Essential to Anterior Neural Development in Xenopus
by: Senturker, Sema, et al.
Published: (2012)

Proprotein Convertases Process Pmel17 during Secretion*
by: Leonhardt, Ralf M., et al.
Published: (2011)

Proprotein convertases in high-density lipoprotein metabolism
by: Choi, Seungbum, et al.
Published: (2013)